SCHEMBL7606176

SCHEMBL7606176

O=CN(c1cccnc1)c1c(OCc2ccccc2)c2ccccc2n1Cc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.44
HDAC1 Q13547 5/20 0.44
PKM P14618 1/20 0.40
LMNA P02545 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
TSHR P16473 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
CYP2C9 P11712 1/20 0.37
KDM4E B2RXH2 2/20 0.37
TDP1 Q9NUW8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606062 0.96 HDAC6 (0.45) HDAC6HDAC1PKMLMNAHDAC8
SCHEMBL7611332 0.91 HDAC6 (0.44) HDAC6HDAC1HDAC8TSHRALDH1A1
SCHEMBL7613735 0.91 HDAC6 (0.44) HDAC6HDAC1HDAC8CYP3A4CYP2C19
SCHEMBL7608458 0.90 HDAC1 (0.40) HDAC6HDAC1PKMHDAC8TSHR
SCHEMBL7612615 0.90 MAPT (0.41) HDAC6HDAC1PKMLMNAALDH1A1
SCHEMBL7613468 0.89 HDAC6 (0.42) HDAC6HDAC1LMNAHDAC8ALDH1A1
SCHEMBL7551884 0.89 HDAC6 (0.44) HDAC6HDAC1HDAC8ALDH1A1MAPK1
SCHEMBL7608926 0.88 LMNA (0.43) HDAC6PKMLMNATSHRALDH1A1
SCHEMBL7555714 0.87 HDAC6 (0.45) HDAC6HDAC1LMNAHDAC8ALDH1A1
SCHEMBL7606049 0.87 PTGIR (0.38) LMNATSHRCYP2D6KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436965-B1 INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2002-08-20 US claimed
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US claimed
US-6436965-B1 INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2002-08-20 US disclosed
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment MERCK FROSST CANADA LTD. (CA) 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068756-A1 PDE IV inhibiting amides, compositions and methods of treatment PDE3A, PDE3B, PDE4A HDAC6 59/4885HDAC1 45/4885PKM 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.